Global University Venturing

Indigo Diabetes increased its total funding to $52.6m with a series B round backed by Imec.xpand and returning investor Qbic.

A panel of international experts at the GCV Digital Forum discusses spinout support going forward.

Comment from Adam Stoten, chief operating officer at Oxford University Innovation.

Comment from David Grimm and Simon Goldman, investment directors of UCL Technology Fund.

South Africa’s venturing market is established as regional leader and further growth from corporate and academic-led initiatives is anticipated.

Tom Hockaday tells us about the key lessons from his tech transfer compendium.

Q2 saw both the highest number of deals and largest sum invested in 18 months.

Covid-19 remains a threat but universities are at the forefront of fighting back.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to UCL and Ludwig Institute.

Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.